Tema Etfs LLC Purchases 18,854 Shares of Zymeworks Inc. $ZYME

Tema Etfs LLC grew its position in Zymeworks Inc. (NYSE:ZYME) by 57.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,855 shares of the company’s stock after purchasing an additional 18,854 shares during the quarter. Tema Etfs LLC owned approximately 0.07% of Zymeworks worth $651,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Kennedy Capital Management LLC lifted its stake in shares of Zymeworks by 7.8% during the 2nd quarter. Kennedy Capital Management LLC now owns 146,954 shares of the company’s stock valued at $1,844,000 after buying an additional 10,635 shares in the last quarter. Invesco Ltd. raised its holdings in Zymeworks by 14.3% during the second quarter. Invesco Ltd. now owns 89,371 shares of the company’s stock valued at $1,122,000 after acquiring an additional 11,165 shares during the period. Panagora Asset Management Inc. bought a new stake in Zymeworks during the second quarter valued at about $421,000. Tejara Capital Ltd lifted its position in shares of Zymeworks by 5.7% in the second quarter. Tejara Capital Ltd now owns 200,150 shares of the company’s stock valued at $2,512,000 after acquiring an additional 10,741 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Zymeworks in the second quarter worth about $2,531,000. 92.89% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Citizens Jmp assumed coverage on Zymeworks in a report on Wednesday. They issued a “market outperform” rating and a $32.00 price target on the stock. JMP Securities set a $32.00 price target on shares of Zymeworks in a report on Wednesday. Leerink Partners set a $37.00 price target on shares of Zymeworks in a research note on Monday, November 17th. JPMorgan Chase & Co. raised their price objective on Zymeworks from $20.00 to $23.00 and gave the company an “overweight” rating in a research report on Thursday, October 16th. Finally, HC Wainwright boosted their target price on Zymeworks from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Zymeworks currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.30.

Zymeworks Stock Up 0.6%

ZYME stock opened at $26.69 on Friday. Zymeworks Inc. has a twelve month low of $9.03 and a twelve month high of $28.49. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -17.79 and a beta of 1.27. The firm’s fifty day simple moving average is $20.20 and its two-hundred day simple moving average is $15.88.

Zymeworks (NYSE:ZYME) last released its earnings results on Thursday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.02. The firm had revenue of $27.61 million during the quarter, compared to analyst estimates of $33.69 million. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The business’s revenue was up 72.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.39) EPS. As a group, equities research analysts expect that Zymeworks Inc. will post -1.39 EPS for the current year.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.